Market news

DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.

Quest Diagnostics (DGX) drew fresh attention after announcing an Apple Health integration that allows iPhone and iPad users to order a preventive lab panel with more than 50 biomarkers for US$119. The Apple Health tie-in lands after a strong run in Quest Diagnostics’ shares, with the price up 15.6% over 90 days and 35.1% year to date, even though the last month’s share price return slipped 3.9% as traders reassessed shorter term risk and reward. Scan beyond Quest Diagnostics and see how other...

Quest Diagnostics has delivered a strong run in recent years, which raises a straightforward question for investors who care about fundamentals. Is the current share price still aligned with the cash the business is expected to generate over time, or has sentiment moved ahead of its underlying economics? Over the past 3 years, Quest Diagnostics has returned 108.9%, which puts real weight on whether that gain is grounded in durable cash flows rather than just multiple expansion. A recent...

The government thinks it's been overpaying Quest Diagnostics. They plan to stop doing that next year.

DGX study finds nearly one-third of Lyme-seropositive patients had antibodies to another tick-borne pathogen, highlighting broader testing needs.

Quest Diagnostics (DGX) and Labcorp (LH) shares fell in Tuesday premarket trading after the Centers

These are the stocks posting the largest moves in early trading.

CMS will cut Medicare lab payments 15% in 2027, impacting Labcorp and Quest. Read more here.

Quest Diagnostics (NYSE:DGX) CEO and President Jim Davis said the diagnostic testing company is exceeding the growth framework it outlined at its prior investor day, driven largely by organic growth, consumer-health demand and partnerships rather than a heavier-than-expected pace of acquisitions. D

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $250.50, accord

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

A new national survey finds the overwhelming majority of American voters rely on diagnostic laboratory testing to guide their healthcare decisions and are deeply concerned about scheduled Medicare payment cuts that could put that access at risk.

Quest Diagnostics (NYSE: DGX) today announced that Apple Health app users in the United States1 will be able to conveniently purchase a tailored Quest laboratory test panel that includes over 50 biomarkers directly through the app on iPhone and iPad later this year. Apple first announced the upcoming update today at its September event.

J. E. Davis disposed of 8% of his direct equity stake under a pre-planned Rule 10b5-1 trading arrangement, retaining $28.9 million in company stock.

In recent months, Renalytix PLC, Humanity Health Inc., and Quest Diagnostics have announced new collaborations and product launches, including a nationwide kidneyintelX.dkd testing program, a Humanity Biological Age wellness add-on on questhealth.com, and expanded AD-Detect blood-based Alzheimer’s tests accessible through Quest’s U.S. collection network. Together, these moves highlight Quest’s push to deepen its role in advanced kidney, brain health, and consumer-oriented wellness testing...

J. E. Davis, Director, CEO, and President, on September 01, 2026, sold 10,000 shares in Quest Diagno

Renalytix (LSE:RENX) has signed a multi-year agreement with Quest Diagnostics to expand access to its kidneyintelX. dkd blood test across the United States.

While Quest Diagnostics has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15, 2026, at 10:50 a.m. Eastern Time.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced two new developments for its Quest AD-Detect® portfolio of blood-based biomarker tests for Alzheimer's disease, with the goal of broadening access to quality blood tests for evaluating symptomatic patients for Alzheimer's disease.

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Quest Diagnostics (DGX) is back in focus after a fresh analyst rating upgrade and a new role powering WHOOP Advanced Labs, which includes access to GRAIL’s Galleri multi cancer early detection test at nearly 2,000 Quest locations. See our latest analysis for Quest Diagnostics. The analyst upgrade and WHOOP partnership come on top of strong momentum in Quest Diagnostics, with the share price at $241.76 and a 30 day share price return of 16.42%. The year to date share price return of 39.11% and...

Quest Diagnostics stock has delivered a strong 3 year return, yet the current checks present a more nuanced picture, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while market based multiples look closer to fair. Quest Diagnostics has returned 92.2% over the past 3 years, which puts extra focus on whether recent gains are already pricing in its cash flow potential. The expansion of WHOOP Advanced Labs, powered in the U.S. by Quest Diagnostics, can...

Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Does Quest Diagnostics (DGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share, payable on October 21, 2026 to shareholders of record of Quest Diagnostics common stock on October 6, 2026.